Clinical Trials on Monoclonal Gammopathy of Renal Significance in Russian Federation
Total 6 results
-
Janssen Research & Development, LLCCompletedMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell NeoplasmUnited States, Belgium, Russian Federation
-
IpsenCompletedRenal Insufficiency, Chronic | Pituitary Diseases | Dwarfism | Turner SyndromeFrance, Germany, Finland, Spain, Belgium, Czechia, Denmark, Greece, Italy, Romania, Russian Federation, Slovakia, Ukraine, United Kingdom
-
Mitsubishi Tanabe Pharma CorporationKureha CorporationCompletedChronic Kidney DiseaseUnited States, Poland, Ukraine, Spain, Argentina, Mexico, Canada, Brazil, Russian Federation, Puerto Rico, Germany, Czechia
-
BayerCompletedHemodialysis | End-stage Renal Disease | Hemodiafiltration | Prevention of Thromboembolic EventsSpain, Greece, Belgium, Russian Federation, Netherlands, Turkey, Japan, Australia, Austria, Bulgaria, Italy, Ukraine, Czechia, Israel, United States, Hungary, Lithuania, Poland, Portugal
-
Novo Nordisk A/SCompletedChronic Kidney Disease | Turner Syndrome | Noonan Syndrome | Chronic Renal Insufficiency | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency | Genetic Disorder | Foetal Growth Problem | Small for Gestational AgeIsrael, Saudi Arabia, Spain, Argentina, Russian Federation, Germany, Netherlands, Italy, Belgium, United Kingdom, Slovenia, Ireland, Sweden, Denmark, Hungary, Finland, Norway, France, Czechia, Lithuania, Luxembourg, Serbia, Switzerland
-
GlaxoSmithKlineCompletedAnaemiaUnited States, Canada, France, Russian Federation, Spain, Australia, United Kingdom, Romania, Brazil, Korea, Republic of, Italy, Poland, Argentina, Mexico